The Democratic Republic of Congo (DRC) and neighboring Uganda are currently grappling with a severe outbreak of the Bundibugyo strain of the Ebola virus, prompting global health bodies to declare it a public health emergency. As of early July, this aggressive viral disease has tragically claimed 600 lives and infected over 1,759 people in the region, highlighting the urgent need for effective interventions. In a significant step forward, an international coalition of health organizations and researchers has launched a groundbreaking clinical trial, known as EBO-PEP, to explore a new strategy for preventing the disease in those most at risk. ## Understanding the Bundibugyo Ebola Threat Ebola virus disease is a severe, often fatal, illness in humans. It is caused by Ebola viruses, which are part of the filovirus family. The Bundibugyo strain is one of several known types, and like others, it can cause hemorrhagic fever, characterized by high fever, severe weakness, muscle pain, headaches, and a sore throat, followed by vomiting, diarrhea, rashes, impaired kidney and liver function, and in some cases, both internal and external bleeding. The virus spreads through direct contact with blood, body fluids (like urine, feces, vomit, semen) of an infected person, or objects contaminated with these fluids. It can also spread through contact with the body of someone who has died from Ebola. What makes the current Bundibugyo outbreak particularly challenging is the absence of specific approved vaccines or treatments directly targeting this particular strain, leaving communities vulnerable and health workers on the front lines in a constant battle against its spread. ## EBO-PEP: A New Strategy for Prevention Recognizing this critical gap, the EBO-PEP clinical trial has been initiated with a clear objective: to evaluate whether an antiviral drug can prevent high-risk individuals from falling ill after they’ve been exposed to the Bundibugyo virus. This approach is called post-exposure prophylaxis (PEP), which means giving medication shortly after potential exposure to prevent the disease from developing. The World Health Organization (WHO) has highlighted this trial as a priority, emphasizing the importance of innovative preventive measures to contain and ultimately stop the current outbreak. The trial, which began recruiting participants on July 14, 2026, is primarily focused in Ituri province in the DRC, an epicenter of the outbreak, and extends to Uganda. Humanitarian organizations like ALIMA (The Alliance for International Medical Action) and Doctors Without Borders (Medecins Sans Frontieres) are providing crucial on-the-ground support, facilitating participant recruitment at specialized PEP centers located next to existing Ebola treatment facilities. ## Obeldesivir: The Investigational Drug The star of this trial is obeldesivir, an experimental antiviral medication developed by Gilead Sciences. This drug is taken orally, making it potentially easier to administer in outbreak settings. Crucially, pre-clinical studies, which are laboratory or animal tests conducted before human trials, have shown that obeldesivir is effective against several filoviruses, including the Bundibugyo virus. This promising early data has paved the way for its evaluation as a preventive treatment in humans, offering a ray of hope in a challenging situation. Participants in the EBO-PEP trial must meet specific criteria: they must be adults or children over 12 years old, have had direct high-risk contact with a confirmed Ebola case (such as a sick person, a corpse, or a contaminated needle-stick injury) within the preceding five days, and crucially, must not be showing any symptoms of the disease themselves. The trial aims to enroll approximately 1,000 participants, who will be closely monitored daily for 21 days, with a final check-up after 42 days, to carefully assess the drug's effectiveness and safety. ## Special Considerations for Vulnerable Populations Understanding that certain populations may react differently to medications, a parallel effort is planned for especially vulnerable groups. For children under 12 years old, and pregnant or breastfeeding women who have had high-risk contact, another antiviral drug, remdesivir, will be offered on a compassionate use basis. This decision stems from the fact that there isn't enough safety data on obeldesivir for these specific groups yet. This careful approach ensures that all individuals with high-risk exposure have access to a potential preventive measure while prioritizing their safety. ## A Global Partnership Driving Progress The EBO-PEP trial is a testament to strong international collaboration. The overall coordination is led by the NGO ALIMA, working alongside a broad consortium of national and international partners. Key scientific leadership comes from institutions like the National Institute for Biomedical Research (INRB) in the DRC, ANRS Emerging Infectious Diseases (ANRS MIE) / Inserm in France, and Mbarara University of Science and Technology (MUST) in Uganda. The Africa Centres for Disease Control and Prevention (Africa CDC) has also played a pivotal role, contributing financially with $1 million and mobilizing additional funds from South Africa and the DRC itself, totaling an extra $5 million. This African leadership and commitment underscore a collective determination to find solutions for health challenges on the continent. This extensive network of partners, including research institutes, universities, and humanitarian organizations, ensures that the trial benefits from diverse expertise and resources. Financial support from the European Commission’s Global Health EDCTP3 partnership further highlights the global commitment to tackling this outbreak and strengthening future pandemic preparedness. ## Strengthening Local Expertise and Future Preparedness Beyond just finding a treatment, the EBO-PEP project also has a vital long-term goal: to strengthen research capabilities within African countries. This includes comprehensive training programs for African researchers across all aspects of clinical trials, from drug safety and data management to patient care and sample collection. By building local expertise, the trial contributes to a more robust, self-sufficient response system for future health crises on the continent. Intensive training sessions have already taken place, preparing local teams for the complexities of conducting such a critical study under challenging conditions. Ultimately, if successful, the EBO-PEP trial could revolutionize how we respond to Ebola outbreaks, offering a critical preventive tool that saves lives and helps bring these devastating epidemics under control more rapidly and effectively. ## The Broader Impact: Preventing Future Outbreaks As Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, aptly noted, prevention is key to stopping this outbreak. The EBO-PEP trial represents a critical opportunity to act before exposure leads to full-blown disease. If successful, post-exposure prophylaxis could become a game-changer, complementing existing public health measures like contact tracing and community engagement. This multi-faceted approach, integrating research with humanitarian action and local capacity building, provides a beacon of hope for communities affected by the Bundibugyo Ebola virus, aiming to safeguard health workers, families, and the wider population from this formidable threat and better prepare the world for future epidemics.